Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Jun 24, 2022; 13(6): 485-495
Published online Jun 24, 2022. doi: 10.5306/wjco.v13.i6.485
Published online Jun 24, 2022. doi: 10.5306/wjco.v13.i6.485
Current treatment landscape for oligometastatic non-small cell lung cancer
Javier Garde-Noguera, Department of Medical Oncology, Hospital Arnau de Vilanova, Valencia 46015, Spain
Margarita Martín-Martín, Lira Pelari-Mici, Department of Radiation Oncology, Hospital Universitario Ramón y Cajal, Madrid 28034, Spain
Andres Obeso, Department of Thoracic Surgery, Hospital Clínico Universitario de Santiago de Compostela, Vigo 15706, Spain
Miriam López-Mata, Department of Radiation Oncology, Hospital Clínico Universitario Lozano Blesa, Zaragoza 50009, Spain
Inigo Royo Crespo, Department of Thoracic Surgery, Hospital Universitari Vall d’ Hebron, Barcelona 08035, Spain
O Juan Vidal, Department of Medical Oncology, Hospital Universitario y Politécnico La Fe, Valencia 46026, Spain
Xabier Mielgo-Rubio, Department of Medical Oncology, Hospital Universitario Fundación Alcorcón, Alcorcón 28922, Madrid, Spain
Juan Carlos Trujillo-Reyes, Department of Thoracic Surgery, Hospital de la Santa Creu I Sant Pau, Barcelona 08029, Spain
Juan Carlos Trujillo-Reyes, Department of Surgery, Universitat Autonoma de Barcelona, Barcelona 08029, Spain
Felipe Couñago, Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Madrid 28223, Spain
Felipe Couñago, Department of Radiation Oncology, Hospital La Luz, Madrid 28003, Spain
Felipe Couñago, Medicine Department, School of Biomedical Sciences, Universidad Europea de Madrid, Villaviciosa de Odón 28670, Madrid, Spain
Author contributions: All authors contributed equally to the writing and critical revision of the manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Javier Garde-Noguera, MD, Consultant Physician-Scientist, Department of Medical Oncology, Hospital Arnau de Vilanova, Carrer de Sant Clement, 12, Valencia 46015, Spain. javiergardenoguera1@gmail.com
Received: April 25, 2021
Peer-review started: April 25, 2021
First decision: June 7, 2021
Revised: June 24, 2021
Accepted: May 12, 2022
Article in press: May 12, 2022
Published online: June 24, 2022
Peer-review started: April 25, 2021
First decision: June 7, 2021
Revised: June 24, 2021
Accepted: May 12, 2022
Article in press: May 12, 2022
Published online: June 24, 2022
Core Tip
Core Tip: The treatment of oligometastatic non-small cell lung cancer patients remains controversial. The lack of solid evidence for the best therapeutic strategy and the multiple options currently available for both systemic and local treatments make this particular population of patients a challenge for clinicians. Improvement of surgical and radiotherapy techniques and the appearance of different ablative methods, such as radiofrequency or cryoablation, have made it possible to radically treat metastases in any location. In addition, recent prospective studies suggest that combining these ablative therapies with systemic treatments improve patient outcomes. We discuss the current status of the management of oligometastatic patients.